Compare Adaptive Biotechnologies Corp (ADPT) vs Invesco Ltd. (IVZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Invesco Ltd. — how do they compare? Adaptive Biotechnologies Corp trades at $20.23 (market cap $3.33B), while Invesco Ltd. trades at $27.06 (market cap $12.15B). The key difference: Invesco Ltd. is far larger — about 3.6× Adaptive Biotechnologies Corp's market cap, and Invesco Ltd. pays a 3.14% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | IVZ | |
|---|---|---|
Market Cap | $3.33B | $12.15B |
Sector | Health | Financials |
52-Week High | $22.37 | $29.44 |
52-Week Low | $10.24 | $16.69 |
Enterprise Value | $3.19B | $22.39B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Invesco (IVZ) trades at $27.40, up 1.44% today, with a bullish technical signal from moving averages and support at $27. The company reported mixed Q1 2026 earnings, missing estimates, but has beaten expectations in two prior quarters. Revenue grew to $6.38B in 2025, though net income was negative at -$281.70M. Operating cash flow remains strong at $1.53B, and a dividend of $0.22 is scheduled for June 2026.
Outlook: Analyst consensus is mixed with 43% buy ratings and a $29.44 price target, suggesting modest upside. Risks include persistent negative profitability and competitive pressures in asset management. The stock offers value with a P/E of 19.48 but requires monitoring of earnings turnaround and expense management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
